Imminent bullish breakoutThe price has been moving within a descending channel for several months, and following the recent earnings report, it's accelerating upward — now positioned just below the upper boundary.
A confirmed close above $880 would set the next target at $935, followed by a potential move beyond $1000.
Ke
Key facts today
Eli Lilly spent about $214 million on U.S. ads for Zepbound and Mounjaro in early 2025, with Zepbound's budget rising to $131 million, reflecting increased marketing amid competition.
Eli Lilly's Mounjaro gained approval for distribution by MedPal Limited in the UK, capturing 79% of the GLP-1 market amid rising obesity and demand for weight loss medications.
Eli Lilly's Trulicity will be part of Medicare price negotiations, with changes effective in 2028. This affects 15 drugs and could impact $20 billion in U.S. sales.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
20.25 USD
10.59 B USD
45.04 B USD
851.56 M
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
Identifiers
3
ISIN US5324571083
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
Eli Lilly Target $1,258-1,316 in final waveStock price is in a bullish impulse
Last wave 5 is in progress
Target is calculated as 50-61.8% of waves 1-3 move added to the valley of wave 4
It is highlighted with the blue box in $1,258-1,316 area
It perfectly aligns with the trend channel resistance
Invalidation is below the bottom of wave 4 <
Eli Lilly (LLY) Holds Uptrend as Buyers Step In at the 50-Day MAEli Lilly & Co. (LLY) continues to attract demand after successfully testing its 50-day moving average. The stock remains in a well-defined uptrend, with price holding above its key moving averages, which are positively aligned—confirming sustained bullish momentum.
NYSE:LLY
Eli Lilly is a $1.02
Lilly - Clean Chart StructureWe are analyzing the move starting from August 2025.
So far, four out of five waves have been drawn.
The structure of the fourth wave is an expanded flat (with measured moves):
A = 134 -> five-wave move (impulse)
B = 156 -> three-wave move
C = 120 -> five-wave move (zigzag, internal impulses ≈
LLY Alert: Katy AI Spots Potential DowntrendLLY QuantSignals Katy 1M Prediction 2026-01-15
🚀 QuantSignals Katy AI Stock Analysis
Analyzed 1 stock(s): LLY
📈 LLY Analysis
Current Price: $1033.38
Final Prediction: $1020.97 (-1.20%)
30min Target: $1050.75 (+1.68%)
Trend: BEARISH
Confidence: 53.0%
Volatility: 37.6%
Summary: Generated 0 trade s
HH printed on Bigger tf.LLY Analysis
CMP 1062.75 (27-01-2026)
HH printed on Bigger tf.
Bearish Divergence may bring the price down.
Immediate Supports seems to be around 1013.
However, breaking 977 may lead it towards 878 - 938
Upside, it has potential to move towards 1250 - 1300 initially if
1135 is Crossed & Sustained
Eli Lilly & NVIDIA: A $1B AI Pharma RevolutionEli Lilly’s $1 billion partnership with NVIDIA signals a seismic shift in pharmaceutical valuation and strategy.
The convergence of biology and silicon is no longer theoretical; it is the new standard for industry leadership. By integrating NVIDIA’s AI supercomputing into its core operations, Eli
Eli Lilly (LLY): Uptrend Intact as GLP-1 Leadership Fuels GrowthEli Lilly continues to hold firmly above its 20- and 50-day EMAs after a healthy retracement, with clear buying interest emerging at the 20 EMA. This price behavior suggests the strong uptrend remains intact and is likely to continue driven by flagship diabetes treatment Mounjaro, obesity drug Zepbo
LLY | This Healthcare Co. Is a Great Pick | LONGEli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapoli
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
LLY5547406
Eli Lilly and Company 5.0% 27-FEB-2026Yield to maturity
5.91%
Maturity date
Feb 27, 2026
XS238628644
Eli Lilly and Company 1.625% 14-SEP-2043Yield to maturity
5.61%
Maturity date
Sep 14, 2043
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064Yield to maturity
5.60%
Maturity date
Aug 14, 2064
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064Yield to maturity
5.59%
Maturity date
Feb 9, 2064
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065Yield to maturity
5.59%
Maturity date
Oct 15, 2065
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065Yield to maturity
5.58%
Maturity date
Feb 12, 2065
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063Yield to maturity
5.58%
Maturity date
Feb 27, 2063
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044Yield to maturity
5.52%
Maturity date
Jun 15, 2044
US532457BU1
Eli Lilly and Company 4.15% 15-MAR-2059Yield to maturity
5.51%
Maturity date
Mar 15, 2059
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054Yield to maturity
5.50%
Maturity date
Feb 9, 2054
LLY6153502
Eli Lilly and Company 5.55% 15-OCT-2055Yield to maturity
5.50%
Maturity date
Oct 15, 2055
See all LLY bonds
Frequently Asked Questions
The current price of LLY is 1,023.80 USD — it has decreased by −2.82% in the past 24 hours. Watch Eli Lilly and Company stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Eli Lilly and Company stocks are traded under the ticker LLY.
LLY stock has fallen by −3.22% compared to the previous week, the month change is a −6.28% fall, over the last year Eli Lilly and Company has showed a 26.83% increase.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLY price has a max estimate of 1,600.00 USD and a min estimate of 830.00 USD. Watch LLY chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLY stock is 3.52% volatile and has beta coefficient of 0.46. Track Eli Lilly and Company stock price on the chart and check out the list of the most volatile stocks — is Eli Lilly and Company there?
Today Eli Lilly and Company has the market capitalization of 982.74 B, it has increased by 2.21% over the last week.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Feb 4, 2026. Keep track of upcoming events with our Earnings Calendar.
LLY earnings for the last quarter are 7.02 USD per share, whereas the estimation was 5.69 USD resulting in a 23.33% surprise. The estimated earnings for the next quarter are 6.95 USD per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to 17.60 B USD, despite the estimated figure of 16.05 B USD. In the next quarter, revenue is expected to reach 17.92 B USD.
LLY net income for the last quarter is 5.58 B USD, while the quarter before that showed 5.66 B USD of net income which accounts for −1.38% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLY dividends are paid quarterly. The last dividend per share was 1.50 USD. As of today, Dividend Yield (TTM)% is 0.58%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.67% in 2024, and payout ratio reached 44.39%. The year before the numbers were 0.78% and 77.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jan 29, 2026, the company has 47 K employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is 28.29 B USD, and current EBITDA margin is 41.75%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eli Lilly and Company technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eli Lilly and Company stock shows the buy signal. See more of Eli Lilly and Company technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.









